Matthew Tiefenbrunn, MD
Family Medicine · Sullivan, MONPI 1457393712
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,500 of the $104,759 with a category attached, or 79.7%. Amgen accounts for 91.8% of it on its own, with 55 other manufacturers making up the rest. 2025 is the largest year on record at $61,238, more than ten times the $672 reported in 2019. Among family medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 665 payments — averaging $157.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$96K
- AbbVie$3K
- Novo Nordisk$674
- Boehringer Ingelheim$555
- Lilly USA, LLC$485
- Pfizer$368
- plus $4K from 50 others
What the payments were for
- Speaking & faculty fees$83,50080%
- Travel & lodging$9,3049%
- Food & beverage$11,90911%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$104,759 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 168 | $177,315 |
| OzempicSemaglutide | 92 | $125,411 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 127 | $96,050 |
| TrulicityDulaglutide | 55 | $82,331 |
| MounjaroTirzepatide | 62 | $76,676 |
| Repatha SureclickEvolocumab | 76 | $50,041 |
| XareltoRivaroxaban | 38 | $40,581 |
| EliquisApixaban | 44 | $39,430 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 123 | $32,811 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 101 | $24,801 |
| FarxigaDapagliflozin Propanediol | 23 | $22,493 |
| ProliaDenosumab | 11 | $19,433 |
| MyrbetriqMirabegron | 39 | $15,011 |
| VascepaIcosapent Ethyl | 36 | $14,024 |
| LinzessLinaclotide | 14 | $12,206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $555 | $183,463180 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $485 | $159,007117 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Incruse Ellipta, Shingrix | $147 | $146,789299 claims |
| Novo NordiskOzempic | $674 | $125,41192 claims |
| PfizerEliquis, Abrysvo | $368 | $64,231145 claims |
| Johnson & JohnsonXarelto | $175 | $40,58138 claims |
| AstraZenecaFarxiga, Symbicort | $215 | $31,16651 claims |
| AmgenProlia | $96,198 | $19,43311 claims |
| AbbVieLinzess, Lumigan | $2,883 | $15,71227 claims |
| Astellas Pharma US IncMyrbetriq | $231 | $15,01139 claims |
| MerckJanuvia | $35 | $8,37711 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCApriso | $128 | $5,52111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Sullivan
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
- Christine MooreRaymore$57K
- Jon MattsonKansas City$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.